Serum miR-30c-5p is a potential biomarker for multiple system atrophy

Area of Science:

• Neuroscience
• Biochemistry
• Genetics

Background:

• Multiple System Atrophy (MSA) and Parkinson's Disease (PD) are α-synucleinopathies with overlapping early clinical symptoms.
• A significant unmet need exists for biomarkers to differentiate MSA from PD due to differing disease progression.
• MicroRNAs (miRNAs) are key regulators of gene expression, found in biofluids, and have shown altered levels in neurodegenerative diseases.

Purpose of the Study:

• To investigate serum miR-30c-5p and miR-148b-5p as potential biomarkers for the early diagnosis of MSA and PD.
• To explore the correlation between the serum levels of these miRNAs and the clinical profiles of patients with MSA and PD.

Main Methods:

• Quantitative PCR (qPCR) was employed to measure the expression levels of miR-30c-5p and miR-148b-5p.
• Serum samples were analyzed from patients diagnosed with PD (n=56), MSA (n=49), and healthy controls (n=50).

Main Results:

• Serum miR-30c-5p was significantly upregulated in MSA patients compared to both PD patients and healthy controls.
• A positive correlation was observed between serum miR-30c-5p levels and disease duration in both MSA and PD cohorts.
• No significant differences in serum miR-148b-5p levels were detected among the three groups.

Conclusions:

• Serum miR-30c-5p shows potential as a diagnostic biomarker for distinguishing MSA from PD.
• The findings suggest that miR-30c-5p may also serve as a biomarker for monitoring disease progression in MSA and PD.